A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back Pain.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back Pain.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Fulranumab (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 18 Apr 2016 Primary endpoint has not been met (Change from baseline in the average low back pain-related pain intensity score) according to the results published in the Clinical Therapeutics.
    • 18 Apr 2016 Results published in the Clinical Therapeutics
    • 10 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top